Used for methemoglobinemia associated with certain drugs (e.g., dapsone, benzocaine, lidocaine), occupational or other exposures to toxic chemicals (e.g., hydrazine, amine-substituted benzenes, nitro-substituted benzenes, nitrates, nitrites), or substance abuse (e.g., inhalation or ingestion of volatile nitrites). Designated orphan drug by FDA for this use.Īccelerated approval of methylene blue for this indication based on reduction (≥50%) in methemoglobin within 1 hour following IV administration of the drug in patients with methemoglobinemia continued FDA approval for this indication may be contingent upon verification of clinical benefits in future clinical studies. Uses for Methylene Blue Methemoglobinemia Oxidation-reduction agent, thiazine dye accelerates conversion of methemoglobin to hemoglobin. May cause serious or fatal serotonin syndrome when used concomitantly with serotonergic drugs.Īvoid concomitant use with drugs that enhance serotonergic transmission (e.g., SSRIs, SNRIs, MAO inhibitors).
Serotonin Syndrome with Concomitant Use of Serotonergic Drugs
0 kommentar(er)
